Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: Controversial or common sense?

European Heart Journal

Volumn 26, Issue 22, 2005, Pages 2361-2367

  Van De Wal, Ruud M A ^a   Van Veldhuisen, Dirk J ^b   Van Gilst, Wiek H ^b   Voors, Adriaan A ^b  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Ace inhibitor; Angiotensin receptor blockade; Cardiovascular disease; Dual blockade; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; LOSARTAN; NAFAMSTAT; VALSARTAN;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; PATIENT; PRIORITY JOURNAL; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SAFETY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DIABETIC NEPHROPATHIES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 27644453447     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi454     Document Type: Review

References (77)

1. Harris P. Evolution and the cardiac patient. Cardiovasc Res 1983;17:437-445.
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
3. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-259.
4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
5. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
6. Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, Chiang YT, Cohn JN. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004;6:937-945.
7. Danilov S, Jaspard E, Churakova T, Towbin H, Savoie F, Wei L, Alhenc-Gelas F. Structure-function analysis of angiotensin I-converting enzyme using monoclonal antibodies: selective inhibition of the amino-terminal active site. J Biol Chem 1994;269:26806-26814.
8. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998;97:1411-1420.
9. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982;4:966-972.
10. Aldigier JC, Huang H, Dalmay F, Lartigue M, Baussant T, Chassain AP, Leroux-Robert C, Galen FX. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans. J Cardiovasc Pharmacol 1993;21:289-295.
11. Miura S, Ideishi M, Sakai T, Motoyama M, Kinoshita A, Sasaguri M. Tanaka H, Shindo M, Arakawa K. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens 1994;12:1177-1181.
12. Jorde UP, Ennezat PV, Lisker J, Suryadevara V, Infeld J, Cukon S, Hammer A, Sonnenblick EH, Le Jemtel TH. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000;101:844-846.
13. Farquharson CA, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:767-775.
14. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Cabrini G, Bonizzato A, Graziani M, Anker SD, Coats AJ, Zardini P. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 2001;37:1808-1812.
15. Waeber B, Brunner HR, Brunner DB, Curtet AL, Turini GA, Gavras H. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 1980;2:236-242.
16. Voors AA, Pinto YM, Buikema H, Urata H, Oosterga M, Rooks G, Grandjean JG, Ganten D, van Gilst WH. Dual pathway for angiotensin II formation in human internal mammary arteries. Br J Pharmacol 1998;125:1028-1032.
17. Voors AA, Oosterga M, Buikema H, Mariani M, Grandjean JG, van Gilst WH. Differences between angiotensin-converting enzyme inhibition and angiotensin II-AT1 antagonism on angiotensin-mediated responses in human internal mammary arteries. J Cardiovasc Pharmacol 2003;41:178-184.
18. van de Wal RMA, Plokker HWM, Lok DJA, Boomsma F, van der Horst FAL, van Veldhuisen DJ, van Gilst WH, Voors AA. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol, in press.
19. Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, Sanz G. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21:53-57.
20. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 1990;265:22348-22357.
21. Rousseau MF, Gurne O, Duprez D, Van Mieghem W, Robert A, Ahn S, Galanti L, Ketelslegers JM. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002;40:1596-1601.
22. Coates D. The angiotensin converting enzyme (ACE). Int J Biochem Cell Biol 2003;35:769-773.
23. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin-converting enzyme inhibition in human subjects. Clin Sci (Lond) 1994;87:567-574.
24. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997;95:1115-1118.
25. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-1292.
26. Vanhoutte PM. Endothelium and control of vascular function: state of the art lecture. Hypertension 1989;13:658-667.
27. Stein JH, Congbalay RC, Karsh DL, Osgood RW, Ferris TF. The effect of bradykinin on proximal tubular sodium reabsorption in the dog: evidence for functional nephron heterogeneity. J Clin Invest 1972;51:1709-1721.
28. Pokharel S, van Geel PP, Sharma UC, Cleutjens JP, Bohnemeier H, Tian XL, Schunkert H, Crijns HJ, Paul M, Pinto YM. Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. Circulation 2004;110: 3129-3135.
29. Tom B, Dendorfer A, Danser AH. Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact? Int J Biochem Cell Biol 2003;35:792-801.
30. Wagenaar LJ, Voors AA, Buikema H, van Gilst WH. Angiotensin receptors in the cardiovascular system. Can J Cardiol 2002;18:1331-1339.
31. Hall KL, Venkateswaran S, Hanesworth JM, Schelling ME, Harding JW. Characterization of a functional angiotensin IV receptor on coronary microvascular endothelial cells. Regul Pept 1995;58:107-115.
32. Wright JW, Harding JW. Brain angiotensin receptor subtypes in the control of physiological and behavioral responses. Neurosci Biobehav Rev 1994;18:21-53.
33. Yamada H, Akishita M, Ito M, Tamura K, Daviet L, Lehtonen JY, Dzau VJ, Horiuchi M. AT2 receptor and vascular smooth muscle cell differentiation in vascular development. Hypertension 1999;33:1414-1419.
34. Dluhy RG, Williams GH. Aldosterone-villain or bystander? N Engl J Med 2004;351:8-10.
35. Struthers AD, MacDonald TM. Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004;61:663-670.
36. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T, DeKock M. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-1609.
37. Moriguchi A, Brosnihan KB, Kumagai H, Ganten D, Ferrario CM. Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol 1994;266:R1273-R1279.
38. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
39. Siragy HM, de Gasparo M, El Kersh M, Carey RM. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 2001;38:183-186.
40. Zachariah PK, Bonnet G, Chrysant SG, DeBacker G, Goldstein R, Herrera J, Lindner A, Materson BJ, Maxwell MH, McMahon FG. Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension. J Cardiovasc Pharmacol 1987;9(Suppl. 3):S53-S58.
41. Morlin C, Baglivo H, Boeijinga JK, Breckenridge AM, Clement D, Johnston GD, Klein W, Kramer R, Luccioni R, Meurer KA. Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension. J Cardiovasc Pharmacol 1987;9(Suppl. 3):S49-S52.
42. Azizi M, Linhart A, Alexander J, Goldberg A, Menten J, Sweet C, Menard J. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. J Hypertens 2000;18:1139-1147.
43. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000;18:89-95.
44. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J 2000;321:1440-1444.
45. Azizi M, Guyene TT, Chatellier G, Wargon M, Menard J. Additive effects of losartan and enalapril on blood pressure and plasma active renin. Hypertension 1997;29:634-640.
46. Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874-1880.
47. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25:95-100.
48. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000;18:89-95.
49. Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18-25.
50. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-124.
51. Ferrari P, Marti HP, Pfister M, Frey FJ. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. J Hypertens 2002;20:125-130.
52. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 2002;62:1020-1025.
53. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-1053.
54. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, Solomon SD, Swedberg K, Van De WF, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-1906.
55. Voors AA, van Veldhuisen DJ. Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT. Int J Cardiol 2004;97:345-348.
56. Juillerat L, Nussberger J, Menard J, Mooser V, Christen Y, Waeber B, Graf P, Brunner HR. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990;16:564-572.
57. Lijnen P, Staessen J, Fagard R, Amery A. Increase in plasma aldosterone during prolonged captopril treatment. Am J Cardiol 1982;49:1561-1563.
58. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-1736.
59. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russell RO, Smith SC Jr. ACC/AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration with the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation 2001;104:2996-3007.
60. van Veldhuisen DJ, Voors AA. Blockade of the renin-angiotensin system in heart failure: the potential place of angiotensin II receptor blockers. Eur Heart J 2000;21:14-16.
61. Carson PE. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. Am Heart J 2000;140:361-366.
62. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-1675.
63. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003;362:767-771.
64. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R, Granger CB, Hradec J, Kuch J, McKelvie RS, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Held P, Solomon SD, Yusuf S, Swedberg K. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004;110:2618-2626.
65. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM, Ryden L, Thygesen K, Uretsky BF. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999;100:2312-2318.
66. Teisman AC, van Veldhuisen DJ, Boomsma F, de Kam PJ, Tjeerdsma G, Pinto YM, de Zeeuw D, van Gilst WH. Chronic beta-blocker treatment in patients with advanced heart failure: effects on neurohormones. Int J Cardiol 2000;73:7-12.
67. Eichhorn EJ, McGhie AL, Bedotto JB, Corbett JR, Malloy CR, Hatfield BA, Deitchman D, Willard JE, Grayburn PA. Effects of bucindolol on neurohormonal activation in congestive heart failure. Am J Cardiol 1991;67:67-73.
68. Cohen SA, Jondeau G, Beauvais F, Berdeaux A. Beneficial effects of carvedilol on angiotensin-converting enzyme activity and renin plasma levels in patients with chronic heart failure. Eur J Heart Fail 2004;6:463-466.
69. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, Marion R, Pecker MS, Sotelo J, August P, Pickering TG, Laragh JH. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999;12:451-459.
70. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582-1587.
71. McKelvie RS, Rouleau JL, White M, Afzal R, Young JB, Maggioni AP, Held P, Yusuf S. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Eur Heart J 2003;24:1727-1734.
72. McAlpine HM, Cobbe SM. Neuroendocrine changes in acute myocardial infarction. Am J Med 1988;84:61-66.
73. Rouleau JL, Moye LA, de Champlain J, Klein M, Bichet D, Packer M, Dagenais G, Sussex B, Arnold JM, Sestier F. Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 1991;68:80D-86D.
74. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004;109:2492-2499.
75. Sica DA. Combination angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy: its role in clinical practice. J Clin Hypertens (Greenwich) 2003;5:414-420.
76. Forclaz A, Maillard M, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003;41:31-36.
77. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002;360:752-760.